Laser for PCV, CSR approved in Europe

Quantel Medical announced that its Vitra photodynamic therapy laser platform has received CE Mark approval. It’s the first platform approved for the treatment of polypoidal choroidal vasculopathy (PCV) and central serous retinopathy (CSR).

Quantel plans to begin commercializing the laser platform immediately in Europe and Asia.

“This comes at an opportune moment, as demand for PDT treatment technologies is expected to increase as the disease’s true prevalence is realized,” said Jean-Marc Gendre, CEO of Quantel Medical. “We’re confident that our world-class laser technology will provide ophthalmologists a quality, cost-effective solution, and are excited to begin commercialization in Europe and Asia.”